Stockreport

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 [TheStreet.com]

Nuvation Bio Inc. Class A  (NUVB) 
PDF PR Newswire NEW YORK, April 21, 2026 Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46. [Read more]